New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Lisata Therapeutics, Inc. (LSTA) vs TScan Therapeutics, Inc. (TCRX)

Lisata Therapeutics, Inc. and TScan Therapeutics, Inc. are both Biotechnology companies. Lisata Therapeutics, Inc. and TScan Therapeutics, Inc. are of similar size ($9.8M and $9.4M). Lisata Therapeutics, Inc. grew revenue faster over the last twelve months: 57.2% against −38.4%. Lisata Therapeutics, Inc. has the higher net margin (−274.9% vs −2,219.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Lisata Therapeutics, Inc. leads on 13 and TScan Therapeutics, Inc. on 4.

Valuation

Metric LSTA TCRX Biotechnology median
P/E n/m n/m 8.49
P/S 0.55 3.76 8.56
P/B 1.10 0.51 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 12.46 0.18 0.69
EV/Sales (18.03) (3.96) 8.00
Earnings yield (208.82%) (589.60%) (35.81%)
Free cash flow yield (258.67%) (572.40%) (25.41%)

Profitability

Metric LSTA TCRX Biotechnology median
Gross margin 14.13% 100.00% 70.18%
Operating margin (398.56%) (2,246.84%) 0.00%
Net margin (274.88%) (2,219.19%) 0.00%
Free cash flow margin (137.78%) (2,152.72%) 0.00%
Return on equity (138.59%) (126.45%) (51.58%)
Return on assets (5.12%) (57.03%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric LSTA TCRX Biotechnology median
Revenue growth (TTM) 57.16% (38.43%) 7.20%
EPS growth (last fiscal year) 20.42% 12.28% 29.04%
Revenue growth, 5-year CAGR — 56.92% 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric LSTA TCRX Biotechnology median
Debt to equity 0.00 0.87 0.00
Current ratio 14.09 2.03 4.79
Net debt to EBITDA 0.88 0.90 1.01

Dividend

Metric LSTA TCRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LSTA TCRX Biotechnology median
Market cap 9.83m 9.42m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack